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Osteoarthritis (OA) is a disease characterized by loss of functional articular cartilage with associated whole
joint pathology and resultant pain and disability, which is projected to affect 59.4 million Americans by 2020.
Unfortunately, there are currently no therapeutics available able to stop or reverse the disease progression
of OA, which can largely be attributed to the variable nature of this disease. As such, there is a need for a
more standardized approach to modeling OA.  
In the current study, our laboratory set out to develop a valid and clinically applicable ex vivo model to
unravel disease mechanisms and evaluate potential treatments for OA utilizing cartilage explants obtained
from tissues discarded after standard-of-care joint surgeries. Cartilage explants were then cut into halves
and cultured individually. 
The specific objectives of this study were to validate consistency of relevant biomarker production between
halves of osteoarthritic cartilage explants, and determine if candidate biomarkers can be detected in human
osteoarthritic cartilage explant culture. A secondary focus of this study was to evaluate the disease-
modifying capabilities of two clinically used therapeutics with this model. By using a ‘split tissue’ approach,
we seek to control for variation in OA development and progression, leading to the identification of targets
for prevention and treatment, as well as biomarkers for early diagnosis, disease staging, prognostication
and treatment monitoring.

